Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.48 |
| ▸ | CDC7 | O00311 | 2/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 4/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.37 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.37 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | F7 | P08709 | 1/20 | 0.36 |
| ▸ | F3 | P13726 | 1/20 | 0.36 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536781 | 0.88 | CAMKK2 (0.47) | CAMKK2MAP2K4MAP2K1ROCK1MAPK1 | |
| SCHEMBL5541202 | 0.87 | CAMKK2 (0.39) | CAMKK2CDC7PIM1RIPK1MAPK8 | |
| SCHEMBL5536725 | 0.86 | CAMKK2 (0.41) | CAMKK2CDC7PIM1RIPK1MAP2K4 | |
| SCHEMBL21802596 | 0.85 | MAP2K1 (0.50) | MAP2K4MAP2K1MAPK1KDR | |
| SCHEMBL5538994 | 0.82 | ROCK1 (0.47) | CDC7ROCK1KDR | |
| SCHEMBL5531182 | 0.82 | MAPK7 (0.47) | CAMKK2CDC7PIM1ROCK1 | |
| SCHEMBL5533791 | 0.81 | KDM4E (0.46) | MAP2K1 | |
| SCHEMBL5537482 | 0.80 | ADORA2A (0.52) | CDC7TTKROCK1MAPK1 | |
| SCHEMBL22044074 | 0.80 | LMNA (0.49) | — | |
| SCHEMBL22044068 | 0.79 | ROCK1 (0.45) | ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | claimed |
| EP-1545515-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | Sugen, Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | claimed |
| WO-2004014368-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | SUGEN, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186716-B2 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1545515-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | Sugen, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | SUGEN, INC. | 2004-05-13 | — | — | US | disclosed |
| WO-2004014368-A1 | 3-PYRROLYL-PYRIDOPYRAZOLES AND 3-PYRROLYL-INDAZOLES AS NOVEL KINASE INHIBITORS | SUGEN, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092546-A1 | 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | MAP3K19, MAP3K1, MAP3K7 | CAMKK2 262/4885CDC7 49/4885PIM1 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.